Exhibit 99.2
China
Biologic Third Quarter 2019 Financial Results
Third Quarter 2019 Financial Performance
Total sales in the third quarter
of 2019 increased by 17.5% in RMB terms, or 14.3% in USD terms, to $136.1 million from $119.1 million in the same quarter of 2018.
Total sales for biopharmaceutical products
(including plasma products and placenta polypeptide products) increased by 18.8% in RMB terms, or 15.5% in USD terms, to $124.3
million from $107.6 million in the same quarter of 2018, as a result of increased sales of most plasma products including human
albumin and IVIG, which was partly offset by decreased sales of placenta polypeptide products. For plasma products, total sales
in the third quarter of 2019 increased by 39.3% in RMB terms, or 35.5% in USD terms, to $119.8 million from $88.4 million in the
same quarter of 2018.
Total sales for biomaterial products in
the third quarter of 2019 increased by 5.7% in RMB terms, or 2.6% in USD terms, to $11.8 million from $11.5 million in the same
quarter of 2018, as a result of higher sales concentration of higher-unit-price artificial dura mater products.
During the third quarter of 2019, human
albumin and IVIG products remained the Company’s two largest sales contributors. Revenue from human albumin increased by
24.6% in RMB terms, or 21.1% in USD terms, from $38.8 million in the third quarter of 2018 to $47.0 million in the third quarter
of 2019. Revenue from IVIG products increased by 51.9% in RMB terms, or 47.9% in USD terms, from $24.2 million in the third quarter
of 2018 to $35.8 million in the third quarter of 2019. As a percentage of total sales, sales from human albumin and IVIG products
were 34.6% and 26.3%, respectively, in the third quarter of 2019.
The sales volume of human albumin products
increased by 24.4% for the third quarter of 2019, with a growth primarily in direct sales to hospitals and inoculation centers,
supplemented by a growth in the distributor channels. The sales volume of IVIG products increased by 55.6% for the third quarter
of 2019 with a growth primarily in the distributor channels, supplemented by a growth in the direct sales channel.
The average price for human albumin remained
stable in RMB terms in the third quarter of 2019 compared to the same quarter of 2018. The average price for IVIG products decreased
by 2.4% in RMB terms over the same quarter of 2018, because of higher sales volume in the distributor channel and lower prices
to certain distributors to enhance our sales volume. In USD terms, the average price for human albumin and IVIG products decreased
by 2.6% and 5.1%, respectively, in the third quarter of 2019 compared to the same quarter of 2018.
Revenue from other immunoglobulin products
increased by 34.5% in RMB terms, or 30.9% in USD terms in the third quarter of 2019 compared to the same quarter of 2018, reaching
17.1% of total sales as compared to 14.9% of total sales in the same quarter of 2018. The revenue increase was mainly attributable
to the increased sales volume of human rabies immunoglobulin and human tetanus immunoglobulin products.
Revenue from other plasma products, including
human coagulation factor VIII, human prothrombin complex concentrate, and human fibrinogen products, increased by 85.4% in RMB
terms, or 80.3% in USD terms, in the third quarter of 2019 compared to the same quarter of 2018, representing 10.1% of total sales
in the third quarter of 2019. The growth was mainly due to increased sales through the distributor channel.
Revenue from placenta polypeptide products
decreased by 75.9% in RMB terms, or 76.6% in USD terms for the third quarter of 2019 as compared to the same quarter of 2018, accounting
for 3.3% of total sales compared to 16.1% of total sales in the third quarter of 2018, mainly because this product was included
in the drug lists for monitoring and prescription control in many regions, which put a downward pressure on its sales volume.
Cost of sales increased by 25.3%
to $47.5 million in the third quarter of 2019 from $37.9 million in the same quarter of 2018. As a percentage of total sales, cost
of sales increased to 34.9% from 31.8% in the same quarter of 2018, mainly due to decreased sales prices for most of the Company’s
plasma products and increased plasma collection costs.
Gross profit increased by 9.1% to
$88.6 million in the third quarter of 2019 from $81.2 million in the same quarter of 2018. Gross margin was 65.1% and 68.2%
in the third quarter of 2019 and 2018, respectively.
Total operating expenses in the
third quarter of 2019 decreased by $16.9 million, or 32.2%, to $35.6 million from $52.5 million in the same quarter of 2018. This
decrease mainly consisted of decreases of $9.7 million in selling expenses, $7.0 million in general and administrative expenses
and $0.2 million in research and development expenses. As a percentage of total sales, total operating expenses decreased to 26.2%
in the third quarter of 2019 from 44.1% in the same quarter of 2018.
Selling expenses in the third quarter
of 2019 decreased by $9.7 million, or 35.4%, to $17.7 million from $27.4 million for the third quarter of 2018. The decrease is
primarily due to the decrease in marketing and promotion expenses related to placenta polypeptide products, which is partly offset
by increased selling expenses for plasma products. As a percentage of total sales, selling expenses decreased to 13.0% in the third
quarter of 2019 from 23.0% in the same quarter of 2018.
General and administrative expenses
in the third quarter of 2019 decreased by $7.0 million, or 31.5%, to $15.2 million from $22.2 million in the same quarter of
2018. As a percentage of total sales, general and administrative expenses decreased to 11.2% for the third quarter of 2019 from
18.6% for the same quarter of 2018. The decrease in general and administrative expenses was mainly due to decreases in legal fees,
one-time provisions and share-based compensation expenses.
Research and development expenses
in the third quarter of 2019 decreased by $0.2 million, or 6.9%, to $2.7 million from $2.9 million in the same quarter of 2018.
As a percentage of total sales, research and development expenses decreased to 2.0% in the third quarter of 2019 from 2.4% in the
same quarter of 2018.
Income from operations in the third
quarter of 2019 increased by 89.9% in RMB terms, or 84.7% in USD terms, to $53.0 million from $28.7 million in the same quarter
of 2018. Operating margin increased to 38.9% in the third quarter of 2019 from 24.1% in the same quarter of 2018.
Income tax expense in the third
quarter of 2019 was $7.6 million compared to an income tax benefit of $3.6 million in the same period of 2018. During the third
quarter of 2018, we reversed $7.5 million U.S. corporate income tax based on the deemed repatriation to the United States of the
Company’s accumulated earnings mandated by the U.S. Tax Reform, according to new regulations and rules issued by the U.S.
Department of the Treasury in August 2018. Excluding the tax reversal impact, the effective income tax rate was 12.4% and 11.5%
for the third quarter of 2019 and 2018, respectively.
Net income attributable to the Company
increased by 46.8% in RMB terms, or 42.9% in USD terms, to $47.0 million in the third quarter of 2019 from $32.9 million in the
same period of 2018. Net margin increased to 34.5% in the third quarter of 2019 from 27.6% in the same period of 2018. Diluted
net earnings per share increased to $1.21 in the third quarter of 2019 compared to $0.94 in the same period of 2018.
Non-GAAP adjusted income from operations
increased by 64.1% in RMB terms, or 59.7% in USD terms, to $61.5 million in the third quarter of 2019 from $38.5 million in the
same period of 2018.
Non-GAAP adjusted net income attributable
to the Company increased by 66.0% in RMB terms and 61.4% in USD terms, to $54.4 million in the third quarter of 2019 from $33.7
million in the same period of 2018. Non-GAAP net margin increased to 40.0% in the third quarter of 2019 from 28.3% in the
same period of 2018. Non-GAAP adjusted net earnings per diluted share increased to $1.40 in the third quarter of 2019 from
$0.96 in the same period of 2018.
Non-GAAP adjusted income from operations
for the third quarter of 2019 excludes $6.5 million in non-cash employee share-based compensation expenses, and $2.0 million in
amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.
Non-GAAP adjusted net income and net
earnings per diluted share for the third quarter of 2019 exclude $5.8 million in non-cash employee share-based compensation
expenses, and $1.6 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.
First Nine Months 2019 Financial
Performance
Total sales in the first nine months
of 2019 increased by 20.0% in RMB terms, or 14.1% in USD terms, to $401.6 million from $351.9 million in the same period of 2018.
Total sales for biopharmaceutical products
increased by 20.8% in RMB terms, or 14.9% in USD terms, to $363.1 million in the first nine months of 2019 from $316.0 million
in the same period of 2018, as a result of increases in the sales of most plasma products, including human albumin, IVIG, hyper-immunoglobulin
and coagulation factor products, which was partly offset by decreases in the sales of placenta polypeptide products. For plasma
products, total sales in the first nine months of 2019 increased by 35.5% in RMB terms, or 28.8% in USD terms, to $339.6 million
from $263.7 million in the same period of 2018. As a percentage of total sales, sales from human albumin and IVIG products accounted
for 38.0% and 23.0%, respectively, in the first nine months of 2019.
Total sales for biomaterial products in
the first nine months of 2019 increased by 12.8% in RMB terms, or 7.2% in USD terms, to $38.5 million from $35.9 million in the
same period of 2018, as a result of higher sales concentration in higher-unit-price artificial dura mater products.
Cost of sales increased by 25.0%
to $136.5 million in the first nine months of 2019 from $109.2 million in the same period of 2018. As a percentage of total sales,
cost of sales increased to 34.0% in the first nine months of 2019 from 31.0% in the same period of 2018, mainly due to decreased
sales prices for most of the Company’s plasma products, and increased plasma collection costs.
Gross profit increased by 9.2% to
$265.1 million in the first nine months of 2019 from $242.7 million in the same period of 2018. Gross margin was 66.0% and
69.0% in the first nine months of 2019 and 2018, respectively.
Total operating expenses in the
first nine months of 2019 decreased by $19.3 million, or 13.9%, to $120.0 million from $139.3 million in the same period of 2018.
This decrease mainly consisted of decreases of $10.4 million in selling expense and $9.8 million in general and administrative
expenses and, partially offset by an increase of $0.9 million in research and development expenses. As a percentage of total sales,
total operating expenses decreased to 29.9% in the first nine months of 2019 from 39.6% in the same period of 2018.
Income from operations in the first
nine months of 2019 increased by 48.0% in RMB terms, or 40.2% in USD terms, to $145.1 million from $103.5 million in the same period
of 2018. Operating margin increased to 36.1% in the first nine months of 2019 from 29.4% in the same period of 2018.
Income tax expense in the first
nine months of 2019 was $23.7 million, compared to $9.8 million in the same period of 2018. During the third quarter of 2018, we
reversed $7.5 million U.S. corporate income tax based on the deemed repatriation to the United States of the Company’s accumulated
earnings mandated by the U.S. Tax Reform, according to new regulations and rules issued by the U.S. Department of the Treasury
in August 2018. Excluding the tax reversal impact, the effective income tax rate was 13.9% and 14.6% for the first nine months
of 2019 and 2018, respectively.
Net income attributable to the Company
increased by 42.6% in RMB terms, or 35.8% in USD terms, to $126.4 million in the first nine months of 2019 from $93.1 million in
the same period of 2018. Net margin increased to 31.5% in the first nine months of 2019 from 26.5% in the same period of
2018. Diluted net earnings per share increased to $3.21 in the first nine months of 2019 compared to $2.66 in the same period
of 2018.
Non-GAAP adjusted income from operations
increased by 30.6% in RMB terms or 23.7% in USD terms to $170.4 million in the first nine months of 2019 from $137.8 million in
the same period of 2018.
Non-GAAP adjusted net income attributable
to the Company increased by 35.2% in RMB terms, or 28.1% in USD terms, to $147.6 million in the first nine months of 2019 from
$115.3 million in the same period of 2018. Non-GAAP net margin increased to 36.8% in the first nine months of 2019 compared
with 32.8% in the same period of 2018. Non-GAAP adjusted net earnings per diluted share was $3.75 and $3.29, respectively,
in the first nine months of 2019 and 2018.
Non-GAAP adjusted income from operations
for the first nine months of 2019 excludes $19.3 million in non-cash employee share-based compensation expenses, and $6.1 million
in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.
Non-GAAP adjusted net income and net
earnings per diluted share for the first nine months of 2019 exclude $16.9 million in non-cash employee share-based compensation
expenses, and $4.4 million in amortization of intangible assets and land use rights related to the acquisition of TianXinFu.
As of September 30, 2019, the Company had
$220.8 million in cash on hand and demand deposits, $465.5 million in time deposits, and $155.0 million in short term investments.
Net cash provided by operating activities
for the first nine months of 2019 was $156.4 million as compared to $71.0 million for the same period of 2018. The $85.4 million
increase in net cash provided by operating activities was a combined result of the increase in net income and a slowdown of increase
in accounts receivable and inventories compared to the first nine months of 2018.
Accounts receivable increased by $19.2
million during the first nine months of 2019 as compared to $47.7 million during the same period of 2018. The accounts receivable
turnover days for plasma products increased to 100 days during the first nine months of 2019 from 94 days during the same period
of 2018, reflecting longer credit terms to hospitals as a result of the nationwide implementation of healthcare reform measures
and intensified competition in the distributor channel.
Inventories increased by $8.9 million in
the first nine months of 2019, which was relatively modest compared to the increase of $34.7 million in the same period of 2018.
This reflected a lower level of albumin inventory attributable to higher-than-expected albumin sales, which was partially offset
by higher IVIG inventory due to sluggish IVIG sales.
Net cash used in investing activities
for the first nine months of 2019 was $37.6 million as compared to $686.2 million for the same period of 2018. During the first
nine months of 2019, the Company paid $21.3 million for the acquisition of property, plant and equipment, intangible assets and
land use rights, and the Company also purchased time deposits and short-term investments in the amount of $1,824.2 million. This
was partly offset by the maturity of time deposits and short term investments of $1,806.3 million, and proceeds from sale of property,
plant and equipment, land use right and intangible assets of $1.6 million. Net cash used in investing activities in the first nine
months of 2018 mainly consisted of payment of $1,680.5 million for purchase of time deposits and short term investments, and payment
of $26.9 million for the acquisition of property, plant and equipment, intangible assets, and land use rights, which was partly
offset by $97.7 million cash received upon acquisition of TianXinFu and the maturity of $923.4 million time deposits and short
term investments.
Net cash used in financing activities
for the first nine months of 2019 was $238.7 million as compared to net cash provided by financing activities of $581.3 million
for the same period of 2018. In the first nine months of 2019, the Company paid $118.9 million for the acquisition of minority
interest in TianXinFu. $110.0 million was remitted to an investment bank by the Company to execute the previously approved share
repurchase program on behalf of the Company. During this period, 1,196,228 shares were repurchased at a total amount of $111.0
million. In addition, the subsidiaries of the Company paid $10.1 million dividend to the non-controlling interest shareholders.
Net cash provided by financing activities in the first nine months of 2018 mainly represented proceeds of $590.3 million from the
issuance and sale of an aggregate of 5,850,000 ordinary shares of the Company to certain investors in late third quarter of 2018.
Non-GAAP Disclosure
This management’s discussion and
analysis of the financial results (this “MD&A”) contains non-GAAP financial measures that exclude non-cash compensation
expenses related to restricted shares and restricted share units granted to employees and directors under the Company's Equity
Incentive Plans and amortization of acquired intangible assets and land use rights. To supplement the Company's unaudited consolidated
financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of
these items in this MD&A. The Company's management believes that its presentation of non-GAAP financial measures provides useful
supplementary information to and facilitates additional analysis by investors. A reconciliation of the adjustments to GAAP results
appears in the table accompanying this MD&A. This additional non-GAAP information is not meant to be considered in isolation
or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP
information provided by other companies.
In addition, as the Company evaluates certain
key items of its financial results on a local currency basis (i.e., in RMB) in addition to the reporting currency (i.e., in USD),
this MD&A contains local currency information that eliminates the impact of fluctuations in foreign currency exchange rates.
The Company believes that, given its operations primarily based in China, providing local currency information on such key items
enhances the understanding of its financial results and evaluation of performance in comparison to prior periods. Changes in local
currency percentages are calculated by comparing financial results denominated in RMB from period to period.
(Financial statements on the following
pages)
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
| | |
For the Three Months Ended | | |
For the Nine Months Ended | |
| | |
September 30, 2019 | | |
September 30, 2018 | | |
September 30, 2019 | | |
September 30, 2018 | |
| | |
USD | | |
USD | | |
USD | | |
USD | |
| Sales: | |
| 136,106,800 | | |
| 119,106,754 | | |
| 401,587,066 | | |
| 351,948,937 | |
| Plasma products: | |
| | | |
| | | |
| | | |
| | |
| Human Albumin | |
| 47,042,092 | | |
| 38,820,347 | | |
| 152,764,552 | | |
| 110,750,427 | |
| Immunoglobulin products: | |
| | | |
| | | |
| | | |
| | |
| Human Immunoglobulin for Intravenous Injection | |
| 35,793,139 | | |
| 24,231,787 | | |
| 92,215,735 | | |
| 84,128,156 | |
| Other Immunoglobulin products | |
| 23,233,110 | | |
| 17,754,624 | | |
| 55,347,850 | | |
| 46,180,028 | |
| Others | |
| 13,762,924 | | |
| 7,634,012 | | |
| 39,272,529 | | |
| 22,672,550 | |
| Placenta Polypeptide | |
| 4,494,989 | | |
| 19,203,232 | | |
| 23,468,860 | | |
| 52,311,027 | |
| Biopharmaceutical products | |
| 124,326,254 | | |
| 107,644,002 | | |
| 363,069,526 | | |
| 316,042,188 | |
| Artificial Dura Mater | |
| 10,936,936 | | |
| 9,976,001 | | |
| 35,818,170 | | |
| 32,735,840 | |
| Others | |
| 843,610 | | |
| 1,486,751 | | |
| 2,699,370 | | |
| 3,170,909 | |
| Biomaterial products | |
| 11,780,546 | | |
| 11,462,752 | | |
| 38,517,540 | | |
| 35,906,749 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost of sales | |
| 47,465,809 | | |
| 37,874,952 | | |
| 136,499,513 | | |
| 109,205,180 | |
| Gross profit | |
| 88,640,991 | | |
| 81,231,802 | | |
| 265,087,553 | | |
| 242,743,757 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| | | |
| | | |
| | | |
| | |
| Selling expenses | |
| 17,737,779 | | |
| 27,441,971 | | |
| 62,108,212 | | |
| 72,489,297 | |
| General and administrative expenses | |
| 15,221,555 | | |
| 22,195,036 | | |
| 50,477,548 | | |
| 60,165,137 | |
| Research and development expenses | |
| 2,688,058 | | |
| 2,898,115 | | |
| 7,450,262 | | |
| 6,560,990 | |
| Income from operations | |
| 52,993,599 | | |
| 28,696,680 | | |
| 145,051,531 | | |
| 103,528,333 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other income (expenses) | |
| | | |
| | | |
| | | |
| | |
| Equity in income of an equity method investee | |
| 202,163 | | |
| 521,213 | | |
| 1,647,174 | | |
| 2,019,767 | |
| Interest expense | |
| (127,416 | ) | |
| (64,563 | ) | |
| (316,225 | ) | |
| (200,236 | ) |
| Interest income | |
| 6,869,914 | | |
| 3,705,168 | | |
| 19,315,786 | | |
| 9,946,304 | |
| Other income, net | |
| 1,228,547 | | |
| 1,181,400 | | |
| 4,810,029 | | |
| 3,807,865 | |
| Total other income, net | |
| 8,173,208 | | |
| 5,343,218 | | |
| 25,456,764 | | |
| 15,573,700 | |
| | |
| | | |
| | | |
| | | |
| | |
| Income before income tax expense | |
| 61,166,807 | | |
| 34,039,898 | | |
| 170,508,295 | | |
| 119,102,033 | |
| | |
| | | |
| | | |
| | | |
| | |
| Income tax expense | |
| 7,630,697 | | |
| (3,614,695 | ) | |
| 23,710,778 | | |
| 9,836,443 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income | |
| 53,536,110 | | |
| 37,654,593 | | |
| 146,797,517 | | |
| 109,265,590 | |
| | |
| | | |
| | | |
| | | |
| | |
| Less: Net income attributable to noncontrolling interest | |
| 6,519,317 | | |
| 4,733,252 | | |
| 20,441,463 | | |
| 16,116,303 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income attributable to China Biologic Products Holdings, Inc. | |
| 47,016,793 | | |
| 32,921,341 | | |
| 126,356,054 | | |
| 93,149,287 | |
| | |
| | | |
| | | |
| | | |
| | |
| Earnings per share of ordinary share: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 1.21 | | |
| 0.94 | | |
| 3.22 | | |
| 2.67 | |
| Diluted | |
| 1.21 | | |
| 0.94 | | |
| 3.21 | | |
| 2.66 | |
| Weighted average shares used in computation: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 38,363,561 | | |
| 33,973,834 | | |
| 38,727,066 | | |
| 33,937,057 | |
| Diluted | |
| 38,435,969 | | |
| 34,077,426 | | |
| 38,812,076 | | |
| 34,078,243 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income | |
| 53,536,110 | | |
| 37,654,593 | | |
| 146,797,517 | | |
| 109,265,590 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other comprehensive loss: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Foreign currency translation adjustment, net of nil income taxes | |
| (38,429,031 | ) | |
| (52,258,441 | ) | |
| (41,802,481 | ) | |
| (64,060,220 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Comprehensive income (loss) | |
| 15,107,079 | | |
| (14,603,848 | ) | |
| 104,995,036 | | |
| 45,205,370 | |
| | |
| | | |
| | | |
| | | |
| | |
| Less: Comprehensive income (loss) attributable to
noncontrolling interest | |
| 4,390,702 | | |
| (1,294,335 | ) | |
| 16,512,010 | | |
| 8,578,116 | |
| | |
| | | |
| | | |
| | | |
| | |
| Comprehensive income (loss) attributable to China
Biologic Products Holdings, Inc. | |
| 10,716,377 | | |
| (13,309,513 | ) | |
| 88,483,026 | | |
| 36,627,254 | |
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| | |
September 30,
2019 | | |
December 31,
2018 | |
| | |
| USD | | |
| USD | |
| ASSETS | |
| | | |
| | |
| Current Assets | |
| | | |
| | |
| Cash and cash equivalents | |
| 220,849,986 | | |
| 338,880,559 | |
| Time deposits | |
| 465,518,691 | | |
| 537,478,040 | |
| Short term investments | |
| 154,990,981 | | |
| 76,048,594 | |
| Accounts receivable, net of allowance for doubtful accounts | |
| 140,332,645 | | |
| 125,115,842 | |
| Inventories | |
| 243,849,082 | | |
| 243,295,512 | |
| Prepayments and other current assets, net of allowance for doubtful accounts | |
| 33,445,505 | | |
| 36,369,275 | |
| Total Current Assets | |
| 1,258,986,890 | | |
| 1,357,187,822 | |
| | |
| | | |
| | |
| Property, plant and equipment, net | |
| 176,184,330 | | |
| 178,327,361 | |
| Intangible assets, net | |
| 45,055,366 | | |
| 53,258,871 | |
| Land use rights, net | |
| 33,023,788 | | |
| 32,204,342 | |
| Equity method investment | |
| 16,556,564 | | |
| 15,428,028 | |
| Prepayments for investments in equity securities | |
| - | | |
| 10,812,893 | |
| Other investments | |
| 10,812,893 | | |
| - | |
| Loan receivable - non current | |
| 35,214,466 | | |
| 39,942,591 | |
| Goodwill | |
| 304,290,906 | | |
| 313,588,803 | |
| Other non-current assets | |
| 12,683,082 | | |
| 9,227,970 | |
| Total Assets | |
| 1,892,808,285 | | |
| 2,009,978,681 | |
| | |
| | | |
| | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| Current Liabilities | |
| | | |
| | |
| Accounts payable | |
| 5,336,009 | | |
| 11,404,642 | |
| Income tax payable | |
| 15,722,067 | | |
| 11,010,347 | |
| Other payables and accrued expenses | |
| 99,175,492 | | |
| 99,933,793 | |
| Total Current Liabilities | |
| 120,233,568 | | |
| 122,348,782 | |
| | |
| | | |
| | |
| Deferred income | |
| 2,386,848 | | |
| 2,824,212 | |
| Non-current income tax payable | |
| 24,905,728 | | |
| 26,899,038 | |
| Other liabilities | |
| 12,874,323 | | |
| 13,203,485 | |
| Total Liabilities | |
| 160,400,467 | | |
| 165,275,517 | |
| | |
| | | |
| | |
| Shareholders’ Equity | |
| | | |
| | |
| Ordinary share: par value $0.0001;
100,000,000 shares authorized; 41,897,901 and 41,616,320 shares issued at September 30, 2019 and December 31, 2018,
respectively; 38,446,969 and 39,361,616 shares outstanding at September 30, 2019 and December 31, 2018,
respectively | |
| 4,190 | | |
| 4,162 | |
| Additional paid-in capital | |
| 1,148,626,812 | | |
| 1,189,698,494 | |
| Treasury share: 3,450,932 shares at September 30, 2019 and 2,254,704 at December 31, 2018, respectively, at cost | |
| (167,432,883 | ) | |
| (56,425,094 | ) |
| Retained earnings | |
| 760,838,792 | | |
| 634,482,738 | |
| Accumulated other comprehensive loss | |
| (83,583,729 | ) | |
| (45,710,701 | ) |
| Total equity attributable to China Biologic Products Holdings, Inc. | |
| 1,658,453,182 | | |
| 1,722,049,599 | |
| | |
| | | |
| | |
| Noncontrolling interest | |
| 73,954,636 | | |
| 122,653,565 | |
| | |
| | | |
| | |
| Total Shareholders’ Equity | |
| 1,732,407,818 | | |
| 1,844,703,164 | |
| | |
| | | |
| | |
| Commitments and contingencies | |
| - | | |
| - | |
| | |
| | | |
| | |
| Total Liabilities and Shareholders’ Equity | |
| 1,892,808,285 | | |
| 2,009,978,681 | |
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | |
For the Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2019 | | |
2018 | |
| | |
USD | | |
USD | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
| Net income | |
| 146,797,517 | | |
| 109,265,590 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
| Depreciation | |
| 11,936,276 | | |
| 10,809,288 | |
| Amortization | |
| 7,052,151 | | |
| 7,391,494 | |
| Loss on sale of property, plant and equipment, land use right and intangible assets | |
| 140,334 | | |
| 119,658 | |
| Fair value changes of short term investments | |
| (1,417,688 | ) | |
| (3,807,868 | ) |
| (Reversal) / allowance for doubtful accounts - accounts receivable, net | |
| (269,239 | ) | |
| 1,125,569 | |
| Reversal for doubtful accounts - prepayments and other receivables | |
| (30,719 | ) | |
| - | |
| Write-down of obsolete inventories | |
| 859,666 | | |
| 428,741 | |
| Impairment for non-current assets | |
| - | | |
| 777,946 | |
| Deferred income tax benefit | |
| (1,855,753 | ) | |
| (6,119,956 | ) |
| Share-based compensation | |
| 19,318,866 | | |
| 27,694,079 | |
| Equity in income of an equity method investee | |
| (1,647,174 | ) | |
| (2,019,767 | ) |
| Change in operating assets and liabilities: | |
| | | |
| | |
| Accounts receivable | |
| (19,226,916 | ) | |
| (47,682,569 | ) |
| Inventories | |
| (8,882,008 | ) | |
| (34,667,723 | ) |
| Prepayments and other current assets | |
| 862,318 | | |
| (11,583,687 | ) |
| Other non-current assets | |
| (698,818 | ) | |
| - | |
| Accounts payable | |
| (2,257,888 | ) | |
| 2,611,758 | |
| Income tax payable | |
| 5,199,606 | | |
| (2,717,011 | ) |
| Other payables and accrued expenses | |
| 4,171,804 | | |
| 30,565,526 | |
| Deferred income | |
| (365,258 | ) | |
| (384,334 | ) |
| Non-current income tax payable | |
| (1,993,310 | ) | |
| (10,769,674 | ) |
| Other liabilities | |
| (1,266,548 | ) | |
| - | |
| Net
cash provided by operating activities | |
| 156,427,219 | | |
| 71,037,060 | |
| | |
| | | |
| | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
| Cash acquired from acquisition of Tianxinfu | |
| - | | |
| 97,702,278 | |
| Purchase of time deposits | |
| (1,253,814,446 | ) | |
| (1,116,354,557 | ) |
| Proceeds from maturity of time deposits | |
| 1,320,433,570 | | |
| 536,098,566 | |
| Purchase of short term investments | |
| (570,426,045 | ) | |
| (564,125,165 | ) |
| Proceeds from maturity of short term investments | |
| 485,851,772 | | |
| 387,319,807 | |
| Payment for property, plant and equipment | |
| (18,821,232 | ) | |
| (26,193,022 | ) |
| Payment for intangible assets and land use rights | |
| (2,440,781 | ) | |
| (700,458 | ) |
| Proceeds from disposal of property, plant and equipment, land use right and intangible assets | |
| 1,595,981 | | |
| 26,785 | |
| Net cash used in investing activities | |
| (37,621,181 | ) | |
| (686,225,766 | ) |
| | |
| | | |
| | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
| Proceeds from stock option exercised | |
| 454,847 | | |
| 1,180,854 | |
| Payment to an investment bank for share repurchase | |
| (110,042,776 | ) | |
| - | |
| Proceeds from the issuance and sale of ordinary shares | |
| - | | |
| 590,265,000 | |
| Acquisition of noncontrolling interest | |
| (118,949,200 | ) | |
| - | |
| Dividend paid by subsidiaries to noncontrolling interest shareholders | |
| (10,124,707 | ) | |
| (10,145,395 | ) |
| Net cash (used
in ) /provided by financing activities | |
| (238,661,836 | ) | |
| 581,300,459 | |
| | |
| | | |
| | |
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH
EQUIVALENTS | |
| 1,825,225 | | |
| 966,642 | |
| | |
| | | |
| | |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | |
| (118,030,573 | ) | |
| (32,921,605 | ) |
| | |
| | | |
| | |
| Cash and cash equivalents at beginning of period | |
| 338,880,559 | | |
| 219,336,848 | |
| | |
| | | |
| | |
| Cash and cash equivalents at end of period | |
| 220,849,986 | | |
| 186,415,243 | |
| | |
| | | |
| | |
| Supplemental cash flow information | |
| | | |
| | |
| Cash paid for income taxes | |
| 22,625,540 | | |
| 30,691,960 | |
| Noncash investing and financing activities: | |
| | | |
| | |
| Acquisition of property, plant and equipment included in payables | |
| 4,792,565 | | |
| 4,781,628 | |
| Set-off loan receivable against accounts payable | |
| 3,656,210 | | |
| - | |
| Land use right acquired with prepayments made in prior periods | |
| 2,689,467 | | |
| - | |
| Fair value of noncash assets acquired and liabilities
assumed in acquisition of TianXinFu | |
| - | | |
| 337,186,892 | |
| Share repurchase using the prepayment to an investment bank | |
| 111,007,789 | | |
| - | |
CHINA BIOLOGIC
PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
| | |
For the Three Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2019 | | |
2018 | |
| | |
USD | | |
USD | |
| Income from Operations | |
| 52,993,599 | | |
| 28,696,680 | |
| Non-cash employee share-based compensation | |
| 6,526,982 | | |
| 7,847,253 | |
| Amortization of acquired intangible assets and land use rights | |
| 1,984,442 | | |
| 1,985,958 | |
| Adjusted Income from Operations - Non GAAP | |
| 61,505,023 | | |
| 38,529,891 | |
| | |
| | | |
| | |
| Net Income Attributable to the Company | |
| 47,016,793 | | |
| 32,921,341 | |
| Non-cash employee share-based compensation | |
| 5,830,180 | | |
| 6,949,127 | |
| Amortization of acquired intangible assets and land use rights | |
| 1,578,945 | | |
| 1,350,452 | |
| Income tax benefit related to U.S. Tax Reform | |
| - | | |
| (7,519,674 | ) |
| Adjusted Net Income Attributable to the Company - Non GAAP | |
| 54,425,918 | | |
| 33,701,246 | |
| Diluted EPS - Non GAAP | |
| 1.40 | | |
| 0.96 | |
| | |
| | | |
| | |
| Weighted average number of shares used in computation of Non GAAP diluted EPS | |
| 38,435,969 | | |
| 34,077,426 | |
| | |
For the Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2019 | | |
2018 | |
| | |
USD | | |
USD | |
| Income from Operations | |
| 145,051,531 | | |
| 103,528,333 | |
| Non-cash employee share-based compensation | |
| 19,318,866 | | |
| 27,694,079 | |
| Amortization of acquired intangible assets and land use rights | |
| 6,075,645 | | |
| 6,615,610 | |
| Adjusted Income from Operations - Non GAAP | |
| 170,446,042 | | |
| 137,838,022 | |
| | |
| | | |
| | |
| Net Income Attributable to the Company | |
| 126,356,054 | | |
| 93,149,287 | |
| Non-cash employee share-based compensation | |
| 16,910,311 | | |
| 25,125,971 | |
| Amortization of acquired intangible assets and land use rights | |
| 4,360,963 | | |
| 4,498,615 | |
| Income tax benefit related to U.S. Tax Reform | |
| - | | |
| (7,519,674 | ) |
| Adjusted Net Income Attributable to the Company - Non GAAP | |
| 147,627,328 | | |
| 115,254,199 | |
| Diluted EPS - Non GAAP | |
| 3.75 | | |
| 3.29 | |
| | |
| | | |
| | |
| Weighted average number of shares used in computation of Non GAAP diluted EPS | |
| 38,812,076 | | |
| 34,078,243 | |
